DGIdb - FINASTERIDE Drug Record

FINASTERIDE chembl:CHEMBL710 ApprovedAntineoplastic

Alternate Names:

PROPECIA
PROSTIDE
AINDEEM
FINASTERIDE
MK-906
PROSCAR
(5ALPHA,17BETA)-(1,1-DIMETHYLETHYL)-3-OXO-4-AZAANDROST-1-ENE-17-CARBOXAMIDE
FINASTERIDA
FINASTERIDUM
PROPECIA®
PROSCAR®
MK906
MK 906
pubchem.compound:57363
drugbank:01216
rxcui:25025
chembl:CHEMBL710
chemidplus:98319-26-7

Drug Info:

FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent
Drug Class	anti-baldness agents
Drug Class	antihyperplasia agents
Year of Approval	1992

(3 More Sources)

Publications:

Bowman et al., 2003, Effects of in utero exposure to finasteride on androgen-dependent reproductive development in the male rat., Toxicol. Sci.
Smith et al., 2009, Finasteride in the treatment of patients with benign prostatic hyperplasia: a review., Ther Clin Risk Manag
Goldenberg et al., 2009, The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme?, Can Urol Assoc J
Ha et al., 2003, Analysis of genetic polymorphisms of steroid 5alpha-reductase type 1 and 2 genes in Korean men with androgenetic alopecia., J. Dermatol. Sci.
Suzuki et al., 2010, Saturable binding of finasteride to steroid 5alpha-reductase as determinant of nonlinear pharmacokinetics., Drug Metab. Pharmacokinet.
Xu et al., 2006, Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers., Clin. Cancer Res.
Joseph et al., 2005, Hidradenitis suppurativa treated with finasteride., J Dermatolog Treat
Sáez et al., 1999, Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride., Prostate
Drury et al., 2009, Inhibition of human steroid 5beta-reductase (AKR1D1) by finasteride and structure of the enzyme-inhibitor complex., J. Biol. Chem.
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Sawaya et al., Androgen responsive genes as they affect hair growth., Eur J Dermatol
Levy et al., 1995, Cloning, expression and functional characterization of type 1 and type 2 steroid 5 alpha-reductases from Cynomolgus monkey: comparisons with human and rat isoenzymes., J. Steroid Biochem. Mol. Biol.
Tian et al., 1994, 17 beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androstan-1-en-3-one is an active site-directed slow time-dependent inhibitor of human steroid 5 alpha-reductase 1., Biochemistry
Thigpen et al., 1992, Four-amino acid segment in steroid 5 alpha-reductase 1 confers sensitivity to finasteride, a competitive inhibitor., J. Biol. Chem.
Rittmaster et al., 1995, Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride., Endocrinology

FINASTERIDE SRD5A2

Interaction Score: 23.78

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Steroid 5-alpha-reductase 2 inhibitor

Trial Name YM-152, finasteride

PMIDs:
12773767 19707263 19543428 12670724 20460827 16818707 16019620

Sources:
TdgClinicalTrial ChemblInteractions TTD
FINASTERIDE AKR1D1

Interaction Score: 9.51

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name YM-152, finasteride

Novel drug target Established target

PMIDs:
19515843

Sources:
TdgClinicalTrial
FINASTERIDE SRD5A1

Interaction Score: 6.66

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name YM-152, finasteride

Novel drug target Established target

PMIDs:
7734398 19707263 8117686 1314830 20460827

Sources:
TdgClinicalTrial TEND
FINASTERIDE CFLAR

Interaction Score: 1.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11399535

Sources:
NCI
FINASTERIDE TGM2

Interaction Score: 0.45

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7835306

Sources:
NCI
FINASTERIDE FGFR1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10386468

Sources:
NCI
FINASTERIDE CYP2C9

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
FINASTERIDE CYP2C19

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
FINASTERIDE CYP1A2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
FINASTERIDE CYP2D6

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
FINASTERIDE CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
FINASTERIDE NFE2L2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
FINASTERIDE AR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: FINASTERIDE
- Version: 01-August-2011
Alternate Names:

FINASTERIDE Primary Drug Name

Drug Info:

Year of Approval 1992

Drug Class antihyperplasia agents

Drug Class anti-baldness agents

Publications:
TdgClinicalTrial: FINASTERIDE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: FINASTERIDE

Version: 14-September-2017

Alternate Names:

C1099 NCI drug code

Drug Info:

Publications:

Sawaya et al., Androgen responsive genes as they affect hair growth., Eur J Dermatol

Rittmaster et al., 1995, Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride., Endocrinology

Sáez et al., 1999, Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride., Prostate

DTC: FINASTERIDE
- Version: 02-September-2020
Alternate Names:

CHEMBL710 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
TTD: Finasteride
- Version: 2020.06.01
Alternate Names:

D08IWD TTD Drug ID

Drug Info:

Publications:
ChemblInteractions: CHEMBL710
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL710
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Direct Interaction	yes
Mechanism of Interaction	Steroid 5-alpha-reductase 2 inhibitor
Trial Name	YM-152, finasteride

Trial Name	YM-152, finasteride
Novel drug target	Established target

FINASTERIDE Drug Record

FINASTERIDE chembl:CHEMBL710 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Steroid 5-alpha-reductase 2 inhibitor Trial Name YM-152, finasteride

PMIDs: 12773767 19707263 19543428 12670724 20460827 16818707 16019620

Sources: TdgClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name YM-152, finasteride Novel drug target Established target

PMIDs: 19515843

Sources: TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name YM-152, finasteride Novel drug target Established target

PMIDs: 7734398 19707263 8117686 1314830 20460827

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11399535

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 7835306

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10386468

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

TEND: FINASTERIDE

Alternate Names: FINASTERIDE Primary Drug Name

Drug Info: Year of Approval 1992 Drug Class antihyperplasia agents Drug Class anti-baldness agents

Publications:

TdgClinicalTrial: FINASTERIDE

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class Small Molecule FDA Approval approved

Publications:

NCI: FINASTERIDE

Alternate Names: C1099 NCI drug code

Drug Info:

DTC: FINASTERIDE

Alternate Names: CHEMBL710 ChEMBL Drug ID

Drug Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

TTD: Finasteride

Alternate Names: D08IWD TTD Drug ID

Drug Info:

Publications:

ChemblInteractions: CHEMBL710

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Steroid 5-alpha-reductase 2 inhibitor

Trial Name YM-152, finasteride

PMIDs:
12773767 19707263 19543428 12670724 20460827 16818707 16019620

Sources:
TdgClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name YM-152, finasteride

Novel drug target Established target

PMIDs:
19515843

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name YM-152, finasteride

Novel drug target Established target

PMIDs:
7734398 19707263 8117686 1314830 20460827

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
11399535

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
7835306

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10386468

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

FINASTERIDE Primary Drug Name

Drug Info:

Year of Approval 1992

Drug Class antihyperplasia agents

Drug Class anti-baldness agents

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Alternate Names:

C1099 NCI drug code

Alternate Names:

CHEMBL710 ChEMBL Drug ID

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Alternate Names:

D08IWD TTD Drug ID